AI Drug Discovery for Pharma and Biotech

Drug discovery

19

drugs

With orphan designations

Overview

Homozygous familial hypercholesterolemia (HoFH) is a rare autosomal dominant or recessive disorder caused by biallelic mutations in LDLR, APOB, PCSK9, or LDLRAP1. It results in lifelong extreme LDL-C elevation (>400 mg/dL untreated), accelerated atherosclerosis, and premature cardiovascular events (often before age 20 without treatment). Diagnosis requires genetic testing and early multimodal therapy to mitigate cardiovascular risk.

Population

  • Prevalence: ~1:160,000–300,000 globally, higher in founder populations (e.g., Québec, Lebanon) [1][6][16]

  • Typically diagnosed in childhood via xanthomas, corneal arcus, or severe dyslipidemia [1][7]

Burden

  • 63–78% develop atherosclerotic CVD by early adulthood [4][9]

  • Real-world LDL-C often remains >160 mg/dL despite therapy [4][13]

  • Standard therapies reduce mortality but 40% remain undertreated [4][9][12]

Therapies

  • First-line: High-intensity statins + ezetimibe (<10–25% LDL-C reduction) [3][13]

  • Add-ons: Lomitapide (VLDL inhibitor), evinacumab (ANGPTL3 antibody; LDL-C ↓43%), PCSK9 inhibitors (if residual LDLR activity) [3][13][17]

  • Procedural: Weekly/biweekly lipoprotein apheresis (LDL-C ↓50–70%) [3][6]

Categories: rare endocrine diseases, rare genetic diseases, rare inborn errors of metabolism

Research Papers

1,412 drug discovery papers about Homozygous familial hypercholesterolemia, with 1 first-in-class and 27 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

1,412 drug discovery papers about Homozygous familial hypercholesterolemia, with 1 first-in-class and 27 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

categories:

Small molecules

cell therapies
2026-09-26 | Real-World Outcomes of Lipoprotein Apheresis in Homozygous Familial Hypercholesterolemia: A Single-Center Longitudinal Experience.

Background: Lipoprotein apheresis (LA) remains an important treatment option for patients with homozygous familial hypercholesterolemia (HoFH) who have persistently severe low- density lipoprotein cholesterol (LDL-C) elevation despite intensive lipid-lowering therapy. Therapeutic plasma exchange (TPE) may serve as a temporary alternative when selective LA is unavailable. Methods: This retrospective, single-center longitudinal observational study evaluated six patients with HoFH treated with double-filtration plasmapheresis (DFPP) between 2010 and 2023. During a temporary interruption in DFPP availability, two patients underwent TPE. Pre- and post-procedure lipid levels were evaluated using paired measurements. Results: A total of 476 DFPP and 20 TPE procedures were performed. During DFPP, the median reductions in total cholesterol and LDL-C were 64.44% [57.14-70.21] and 67.53% [59.53-73.86], respectively, while the median reductions in high-density lipoprotein cholesterol (HDL-C) and triglycerides were 40.00% [30.63-48.00] and 48.63% [35.38-57.66]. Among TPE procedures with paired measurements, the corresponding median reductions were 71.11% [65.52-72.69] for total cholesterol, 70.97% [67.14-73.72] for LDL-C, 67.08% [62.92-70.83] for HDL-C, and 55.73% [38.68-63.33] for triglycerides. No serious adverse events were observed during DFPP. TPE was discontinued in one patient after chills and subfebrile fever. Conclusions: Long-term DFPP was associated with substantial acute lipid reductions in patients with HoFH. TPE also produced marked acute lipid reductions in two patients when DFPP was unavailable. However, the limited number of TPE-treated patients, repeated procedures within the same individuals, and overlapping evolocumab exposure preclude conclusions regarding comparative efficacy or safety. TPE may be considered as an individualized interim option when selective lipoprotein apheresis is temporarily unavailable.

Open article ↗



2026-06-26 | Women with Homozygous Familial Hypercholesterolemia and Impact on Reproductive Life from Menarche to Menopause: Long-Term Case Series Observational Study

Homozygous familial hypercholesterolemia (HoFH) is a genetic disease in which LDL-C is high at birth, causing cardiovascular disease. Reproductive issues in women are also caused by lipid-lowering therapies (LLTs) that must be interrupted during pregnancy and breastfeeding. The only safe choice during pregnancy is lipoprotein apheresis (LA), although there are limited data regarding fertility, pregnancy, and menopause. This long-term case series observational study examined 23 genetically confirmed HoFH women in a tertiary health facility, obtaining clinical, cardiovascular, biochemical, and reproductive information through medical records and structured interviews. Cardiovascular disease and aortic valve disease were found in 48% and 52%, respectively; four women died prematurely. Menarche (12.1 years) and menopause (52.0 years) were in the normal range. The majority of these had regular menstrual cycles; there was one case of polycystic ovary syndrome. Twelve women became spontaneously pregnant. Obstetric complications included preterm delivery, gestational diabetes, hypertension, and fetal growth restriction. This study showed that continuous LA during pregnancy was associated with better lipid control and maternal-fetal outcomes, but cardiovascular impairment was observed in the case of interruption of LLT. LLT interruption affects the inherited lipid disorder, and a very short period of breastfeeding is recommended. HoFH in women under treatment has no impact on the menstrual cycle or on the timing of menopause. Pregnancy is a high-risk condition that needs the care of a multidisciplinary team. The need to ensure continuous LA, systematic reproductive counseling, early cardiovascular examination, and aligned lifelong care is critical in maximizing the outcome of HoFH women.

Open article ↗



2026-06-24 | Synergistic "targeting and blockade" strategy via engineered exosomes and clinical ultrasound contrast agent for hepatocyte-targeted mRNA delivery.

Homozygous familial hypercholesterolemia (HoFH) presents a persistent and difficult-to-treat condition. This recalcitrance stems largely from loss-of-function mutations within the low-density lipoprotein receptor (LDLR) gene, which severely undermine the efficacy of standard therapeutic regimens. Here, we report a bioinspired "targeting and blockade" strategy for the efficient delivery of functional Ldlr mRNA to hepatocytes. This approach is realized through a rationally designed platform, Szd + AP@ExoE-Ldlr, which integrates APOA1-functionalized exosomes for hepatocyte-targeted delivery with a preemptive macrophage blockade using the clinical ultrasound contrast agent Sonazoid (Szd). The APOA1 modification confers specific recognition by the scavenger receptor class B type 1 on hepatocytes, while the pre-saturation of Kupffer cells with Szd significantly mitigates nonspecific clearance by the mononuclear phagocyte system (MPS). In a HoFH murine model, this synergistic strategy markedly enhanced the accumulation of exosomes in hepatocytes and achieved robust restoration of hepatic LDLR expression. Consequently, it elicited a profound correction of the atherogenic lipid profile and substantially attenuated the progression of atherosclerosis. A comprehensive biosafety evaluation confirmed the excellent biocompatibility of this platform. Our work provides a promising and broadly applicable solution for the treatment of liver-related genetic disorders by simultaneously overcoming the critical barriers of targeted delivery and MPS evasion.

Open article ↗



2026-04-17 | Liver transplantation in severe homozygous familial hypercholesterolaemia: a scoping review.

Liver transplantation is the only known potentially curative treatment for homozygous familial hypercholesterolaemia (HoFH). While this procedure often normalises low-density lipoprotein cholesterol (LDL-C) levels and can reverse coronary atherosclerosis and regress xanthomata, its long-term risks and benefits remain elusive. The purpose of this review was to examine the extant literature on the safety and efficacy of liver transplantation in patients with HoFH. A scoping review was conducted for relevant literature primarily focused on safety (e.g. surgical complications, rejection, immunosuppressive therapy, mortality) and effectiveness outcomes (e.g. serum LDL-C levels, xanthoma changes, atherosclerotic cardiovascular disease or events) of liver transplantation in severe HoFH. The PRISMA-ScR guideline was followed. We searched five databases (Medline, Embase, Global Health, Web of Science and CINAHL) from inception to September 2025. A total of 76 studies and 212 cases were included. The majority (53%) of studies were case reports. Liver transplantation was done mostly in children, genetically or phenotypically diagnosed with HoFH. The median follow-up time for individuals was 3.5 years. While the effectiveness of liver transplantation with reference to LDL-C reduction and xanthomata regression were well documented, long-term outcomes such as cardiovascular events and mortality were not consistently reported. While liver transplantation holds great potential for normalising circulatory LDL-C levels in patients with HoFH, due to the rare nature of HoFH, the current literature remains incomplete concerning its safety and efficacy. To fill this gap, future efforts should utilise liver transplantation registries, to increase sample size and standardise longer-term follow-up.

Open article ↗



2026-01-21 | Clinical and Subclinical Atherosclerotic Disease in Adolescents With Familial Hypercholesterolemia.

Familial hypercholesterolemia is primarily a disorder of reduced low-density lipoprotein (LDL) clearance, which can be inherited in either homozygous or heterozygous form. Despite the availability of various modalities to achieve target LDL cholesterol levels, inadequate control remains a significant risk factor for accelerated atherosclerosis in the pediatric population. Moreover, the occurrence of coronary artery disease in adolescents poses unique management challenges given the limited representation of this age group in clinical trials. We report 2 cases of coronary artery disease and 1 case of subclinical atherosclerosis in adolescent patients with genetically confirmed familial hypercholesterolemia, outlining the diagnostic work-up, challenges in achieving LDL cholesterol control, measures undertaken, including plasma exchange, and revascularization strategies using drug-eluting stents or drug-coated balloons, in accordance with current guidelines.

Open article ↗



small molecules
2026-09-18 | Current, novel and emerging lipid-lowering therapies in pediatric familial hypercholesterolemia.

Over the past decade, pharmacological treatment options for children with familial hypercholesterolemia (FH) have expanded considerably. The recent European Atherosclerosis Society consensus recommends more stringent LDL cholesterol (LDL-C) targets than previously advocated. Consequently, more children with FH are expected to become eligible for novel therapeutic options. This review summarizes established and emerging lipid-lowering therapies (LLT) evaluated in children, focusing on recent and ongoing clinical trials. Conventional LLT remains the cornerstone of FH treatment, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are approved for pediatric use and achieve significant LDL-C reductions; however, injectable administration and high costs limit their widespread use. Novel oral PCSK9 inhibitors are currently under investigation in clinical trials, and fixed-dose combinations may offer a more practical and cost-effective approach. Additionally, angiopoietin-like protein 3 inhibitors and microsomal triglyceride transfer protein inhibitors lower LDL-C in dependently of LDL receptor activity, making them particularly suitable for homozygous FH patients. The management of FH is entering a new therapeutic era. As therapeutic options expand and agents with greater LDL-C reductions become available, personalized treatment strategies will become increasingly important to achieve LDL-C targets and may ultimately shift from stepwise intensification approaches toward early intensive treatment.

Open article ↗



2026-08-01 | Lipoprotein apheresis: still needed in many patients, or soon a historical practice?

Abstract Lipoprotein apheresis (LA) has long been used as an ultima ratio therapy for patients with extreme lipid-driven cardiovascular risk. One perspective maintains that, despite major advances in lipid-lowering pharmacology and the emergence of gene-silencing therapies, LA remains indispensable for selected patients with homozygous familial hypercholesterolemia (HoFH), severe hypercholesterolemia refractory to maximal therapy, and isolated lipoprotein(a) [Lp(a)]–mediated progressive cardiovascular disease. An opposing view argues that modern and emerging pharmacological agents—PCSK9 inhibitors, inclisiran, bempedoic acid, evinacumab, and targeted Lp(a)-lowering antisense and small interfering RNA (siRNA) agents—have already rendered LA obsolete in almost all patients, with its remaining niche closing rapidly as outcome data accumulate. This combined manuscript juxtaposes the two positions in a streamlined form and concludes with a balanced conclusion of the future role of LA.

Open article ↗



2026-05-01 | Triazine Thiols Decrease Apolipoprotein B Secretion From Hepatocytes Through Inhibition of Human Carboxylesterase 1.

Homozygous familial hypercholesterolemia is an autosomal genetic disorder that generates increased levels of low-density lipoproteins in the serum. Elevated low-density lipoprotein results in hypercholesterolemia leading to potentially fatal cardiovascular disease. Patients with homozygous familial hypercholesterolemia are often refractory to standard cholesterol-lowering treatments. Some available pharmaceuticals developed specifically for homozygous familial hypercholesterolemia can elevate hepatic lipid levels and in other cases have limited accessibility. Previously, we identified a family of triazine thiol compounds that effectively reduce apolipoprotein B-100 secretion by hepatocytes. In mice with humanized livers, triazine thiols effectively lowered serum cholesterol, triglycerides, low-density lipoproteins and lipoprotein(a). Despite their effectiveness, the mode of action of triazine thiols was unknown. Affinity-based mass spectrometry, biochemical assays, molecular modeling, and gene-edited induced pluripotent stem cell-derived hepatocyte-like cells were used to identify and characterize the molecular target and mechanism of action of triazine thiols. Using affinity-based mass spectrometry, we identified Carboxylesterase 1 (CES1) as a triazine thiol binding protein. Biochemical assays demonstrated that triazine thiols are slow-binding, allosteric, covalent CES1-specific inhibitors. Molecular modeling identified a predicted binding site within CES1 near cysteine 390, and loss of this cysteine conferred resistance to triazine thiol-mediated inhibition. Moreover, hepatocyte-like cells derived from CES1-/- induced human pluripotent stem cells exhibited a significant reduction in APOB secretion, mimicking the effect of triazine thiol treatment. This study establishes triazine thiols as novel, highly specific carboxylesterase 1 inhibitors, providing insight into their mechanism and highlighting carboxylesterase 1 inhibition as an approach for treating hypercholesterolemia.

Open article ↗



2026-02-14 | The evolving therapeutic landscape of PCSK9 inhibition.

Cardiovascular disease remains the leading cause of death worldwide with low density lipoprotein being a major, yet modifiable, risk factor. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a central role in regulating low density lipoprotein (LDL) receptor expression. Naturally occurring loss-of-function variants in the PCSK9 gene result in lifelong lower LDL cholesterol (LDL-C) levels and significantly lower risk of atherosclerotic cardiovascular disease (ASCVD), providing strong genetic validation of PCSK9 as a therapeutic target. This insight has driven the development of therapies directed at PCSK9 for the management of hypercholesterolaemia, particularly in patients who fail to meet LDL-C targets despite maximally tolerated statin and ezetimibe. This is especially the case for patients who are statin intolerant or who have homozygous or heterozygous familial hypercholesterolaemia. The field has progressed rapidly from monoclonal antibodies to small interfering RNA and oral therapies, with gene editing strategies offering a potentially permanent inhibition of PCSK9. This review summarizes the evidence supporting the currently approved PCSK9 inhibitors. We discuss some novel therapies that are currently in development and consider some expanding indications for PCSK9 inhibition.

Open article ↗



2026-02-02 | Where lipoproteins meet T cells: LDL receptor in the growing landscape of immune modulation

T cells are highly adaptable immune cells that play a central role in host defense against infections, malignancies, and other threats. For effective immune responses, T cells must rapidly switch from a resting state to an active, energy-demanding state after recognizing antigen, and subsequently return to a quiescent state once the threat has been cleared. Tight regulation of this dynamic process is essential for immune homeostasis, as uncontrolled or prolonged T cell activation can result in chronic inflammation, tissue damage, or the development of autoimmune disease. T cell function is closely linked to intracellular metabolism. Nutrient uptake and energy metabolism are now recognized as key determinants of T cell activation, differentiation, and function. Within this context, the role of lipid metabolism, and specifically the use of lipoproteins by T cells, remains incompletely understood. Lipoproteins are the primary transporters for lipids such as cholesterol and triglycerides in the circulation. Low-density lipoprotein (LDL) delivers cholesterol to peripheral tissues, where it is essential for membrane synthesis, hormone production, and cellular growth. Cellular LDL uptake is largely mediated by the LDL receptor (LDLR), which is expressed by many cell types, including immune cells. Despite the fundamental importance of this pathway, its role in T cell biology has remained poorly characterized. This thesis investigates whether T cell responses can be modulated through manipulation of lipoprotein uptake and metabolism. Chapter 2 establishes a conceptual framework by introducing the field of immunometabolism, outlining how metabolic pathways and nutrient availability shape immune cell behavior, and highlighting their relevance in chronic inflammatory diseases such as atherosclerosis and cancer. Chapter 3 uncovers an immunological role for lipoproteins as carriers of lipid antigens, showing that circulating lipoproteins can transport lipid antigens to invariant natural killer T (iNKT) cells and induce their activation. Chapters 4 and 5 further delineate the role of LDLR-dependent lipoprotein uptake in CD4+ and CD8+ T cell subsets. Using cells derived from patients with homozygous familial hypercholesterolemia (hoFH), with mutations in the LDLR, this work demonstrates the importance of LDLR-mediated lipoprotein uptake in T cell function. LDLR-mediated uptake shaped CD4+ T cell activation, proliferation, and differentiation, particularly promoting the development of IL-10-producing immunoregulatory CD4+ T cells. In CD8+ T cells, PCSK9-mediated downregulation of LDLR impaired activation and effector function, whereas pharmacological inhibition of PCSK9 restored cytotoxic capacity, revealing opportunities to repurpose cholesterol-lowering therapies to enhance cancer immunotherapy. Chapter 6 explores strategies to improve tumor antigen presentation by increasing MHC class I expression, thereby enhancing CD8+ T cell-mediated tumor recognition. Finally, Chapter 7 emphasizes the metabolic flexibility of T cells, underscoring the therapeutic potential and complexity of targeting interconnected metabolic networks to modulate immune responses. Together, these findings establish lipoprotein metabolism as a key modulator of T cell immunity and underscore metabolic pathways as promising, though complex, targets for therapeutic intervention.

Open article ↗



oligonucleotides
2026-09-17 | Predictors of aortic stenosis in homozygous familial hypercholesterolemia: A study from the Canadian HoFH registry.

Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disease of low-density lipoprotein cholesterol (LDL-C) metabolism. This disease is associated with a major risk of both atherosclerotic cardiovascular disease and aortic stenosis (AS). The predictors of AS in this population are not well established. To investigate the univariable and multivariable predictors of AS in patients from the Canadian HoFH registry. Individuals from the Canadian HoFH registry were included in this retrospective longitudinal study. Clinical data were obtained from the treating physicians using a standardized questionnaire. Cox proportional hazards models were used to investigate the predictors of AS. The observed lifetime risk of AS was calculated using Kaplan-Meier estimates. Among the 67 patients with HoFH, 25 (37%) developed AS. The mean age at baseline was 22 ± 17 years and women represented 57% of the cohort. The independent predictors of AS were the baseline LDL-C (hazard ratio [HR] 1.22 [1.09-1.35], P = .0003) as well as the presence of at least 1 null genetic variant (HR 3.73 [1.41-9.86], P = .008). Having a baseline LDL-C value above 13 mmol/L was associated with an observed lifelong risk of developing AS approaching 100% within this cohort, whereas having a value below this threshold was associated with a risk of 27% (P = .0002). This is the first systematic evaluation within a national HoFH registry to report the univariable and multivariable predictors of AS in patients with HoFH. An external validation of our results in an international cohort of HoFH is warranted.

Open article ↗



2026-09-15 | Emerging Nucleic Acid-Based Therapies for Hypercholesterolemia with Focus on a New Modality, Liver-Directed miR-30c Analog C2.

Despite major advances in lipid-lowering therapies, a significant unmet need remains, particularly for patients with homozygous familial hypercholesterolemia (HoFH), severe heterozygous familial hypercholesterolemia (HeFH), and those who fail to achieve guideline-recommended LDL-C targets. Nucleic acid-based therapeutics have emerged as a transformative approach for treating hypercholesterolemia. Antisense oligonucleotides and small interfering RNAs (siRNAs) have demonstrated durable hepatic gene silencing and have led to approved therapies, while gene replacement and in vivo genome-editing strategies offer the potential for long-lasting, and possibly one-time, interventions. In parallel, microRNAs (miRNAs) have attracted increasing interest because of their ability to coordinately regulate multiple genes involved in lipoprotein metabolism, cholesterol transport, and lipid homeostasis. Human genetic studies further support the importance of miRNA-mediated regulation, exemplified by a rare ~2.5 kb deletion in the distal LDLR 3'UTR ("del2.5") that disrupts miRNA-binding sites and is associated with lifelong low LDL-C levels. This review summarizes recent advances, mechanisms of action, clinical progress, and remaining challenges across antisense oligonucleotides, siRNAs, gene therapy, genome editing, and emerging miRNA-based therapeutics for hypercholesterolemia. As an example of the latter approach, the liver-directed miR-30c analog C2 has demonstrated preclinical activity by coordinately reducing hepatic lipoprotein secretion and lipogenesis while enhancing cholesterol elimination, resulting in reduced LDL-C and atherosclerosis. However, it must be noted that these findings remain preclinical, and further optimization of delivery, pharmacokinetics, safety, and long-term efficacy will be required before clinical evaluation. Continued advances in RNA chemistry, targeted delivery, and genome engineering are expected to further expand the therapeutic landscape for dyslipidemia and cardiovascular disease.

Open article ↗



2026-06-04 | New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering.

ApoB is the structural protein of all atherogenic lipoproteins, including VLDLs (very-low-density lipoproteins), IDLs (intermediate-density lipoproteins), LDLs (low-density lipoproteins), chylomicron remnants, as well as Lp(a) (lipoprotein[a]). Because each lipoprotein particle contains a single apoB molecule, plasma apoB concentration reflects the number of circulating atherogenic particles. Genetic, epidemiological, and randomized clinical trial evidence consistently demonstrate that, on a per-particle basis, apoB is a more accurate causal determinant of atherosclerotic cardiovascular disease risk than LDL cholesterol alone. Beyond atherosclerosis, apo B48-containing chylomicrons play a central role in severe hypertriglyceridemia and, importantly, contribute to the risk of triglyceride-mediated acute pancreatitis. Most established therapies that reduce major cardiovascular events, including statins, ezetimibe, PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, and bempedoic acid, act primarily by enhancing LDL receptor-mediated clearance of apoB-containing particles. Other currently available therapies reduce LDL cholesterol as well as apoB through LDL receptor-independent mechanisms. Lomitapide, an inhibitor of MTP (microsomal triglyceride transfer protein), and evinacumab, a monoclonal antibody targeting ANGPTL3 (angiopoietin-like protein 3), reduce LDL cholesterol in homozygous familial hypercholesterolemia by decreasing triglyceride-rich apoB-containing lipoproteins upstream of LDL particle formation. Emerging therapeutic strategies targeting the angiopoietin-like protein axis, apo CIII, Lp(a), CETP (cholesteryl ester transfer protein), hepatic lipid flux, and incretin signaling expand the therapeutic landscape for modulating apoB-containing lipoproteins. Gene-targeted approaches, including gene editing, epigenome editing, small interfering RNA, and antisense oligonucleotides, as well as novel oral or injectable agents and combination therapies, further broaden opportunities for durable apoB modulation. Transitioning from an LDL cholesterol-centric to an apoB-centric framework may represent a biologically integrated strategy to reduce both atherosclerotic cardiovascular disease and triglyceride-mediated pancreatitis risk.

Open article ↗



2026-02-28 | Variable phenotype associated with compound LDLR gene mutations in familial hypercholesterolemia patients: Case series and clinical implications.

Homozygous familial hypercholesterolemia (HoFH) is a rare inherited disorder with an extremely elevated level of low-density lipoprotein (LDL) cholesterol (LDL-C) and accelerated premature coronary artery disease (PCAD). It is primarily caused by a single pathogenic variant of the LDL receptor (LDLR) gene. This report presents 2 rare and unrelated cases of HoFH with compound LDLR mutations. These 2 individuals presented with atypical clinical features and demonstrated variable degrees of hypercholesterolemia. Case 1 is a 36-year-old Malay woman identified during family cascade screening with a pretreated LDL-C of 8.5 mmol/L and a strong family history of PCAD. Case 2 is a 58-year-old Indian woman discovered to have a pretreated LDL-C of 5.2 mmol/L during routine health screening, without a significant family history of hypercholesterolemia or PCAD. Neither patient demonstrated tendon xanthomas or other lipid stigmata. Both patients underwent lipid profiling and targeted next-generation sequencing of FH-related genes (LDLR, APOB, PCSK9, ABCG5, and ABCG8). Two novel LDLR variants were identified in exon 18: c.2548-1_2548delGAinsTC (pathogenic) and c.2556_2557insTCAGTCTGG (p.Leu853Serfs*12; likely pathogenic) and classified according to American College of Medical Genetics and Genomics guidelines. Case 1 was homozygous for both variants, while Case 2 was homozygous for the splice-site variant and heterozygous for the frameshift variant. Both patients received guideline-directed lipid-lowering therapy and ongoing cardiovascular risk management. Despite biallelic LDLR variants, both patients demonstrated relatively milder hypercholesterolemia and absence of classical HoFH stigmata. The LDLR variants located in exon 18 affecting the cytoplasmic tail domain may be associated with attenuated clinical expression. Recognition of genotype-phenotype variability is crucial for accurate diagnosis, risk stratification, and individualized management of HoFH.

Open article ↗



2026-02-14 | A nationwide genetic and phenotypic spectrum of 63 probands of homozygous familial hypercholesterolemia in Taiwan.

The genetic and phenotypic spectrum of homozygous familial hypercholesterolemia (HoFH) in Han Chinese populations remains insufficiently defined. To delineate the nationwide genetic and clinical features of HoFH in Taiwan, including true HoFH, double heterozygous FH (HeFH), and compound HeFH. Patients with clinically diagnosed probable or definite FH enrolled in the Taiwan FH Registry who underwent genetic testing between 2006 and 2025 were analyzed. A comprehensive workflow integrating microarray assay, mass spectrometry, targeted next-generation sequencing, and multiplex ligation-dependent probe amplification was implemented. Variants were classified using American College of Medical Genetics and Genomics guidelines. Of 1479 screened individuals, 63 were genetically confirmed to have HoFH (mean age, 32.8 ± 22.7 years), including 28.6% with atherosclerotic vascular disease. The cohort comprised 14 true HoFH (including homozygous APOB variants), 6 double HeFH, and 43 compound HeFH. The highest documented low-density lipoprotein cholesterol (LDL-C) levels were 357.3 ± 123.5 mg/dL in true HoFH, 347.3 ± 39.2 mg/dL in double HeFH, and 443.5 ± 170.9 mg/dL in compound HeFH. The most frequent genotypes were LDLR [IVS2+4A>T];[IVS2+4A>T] in true HoFH, [APOB p.R3527W];[LDLR IVS2+4A>T] and [APOB p.R3527W];[LDLR p.D90N] in double HeFH, and LDLR [p.D90N];[p.C329Y] in compound HeFH. Patients with double HeFH had lower LDL-C levels and fewer xanthomas than those with LDLR homozygosity or compound mutations, while individuals with homozygous LDLR exon deletions/duplications had the highest LDL-C levels. This nationwide study provides the first comprehensive genetic and clinical characterization of HoFH in Taiwan. Our findings highlight the importance of precise genetic diagnosis and early detection strategies in improving outcomes for this high-risk population.

Open article ↗



antibodies
2026-09-23 | Evinacumab Enables Discontinuation of LDL Apheresis in Homozygous Familial Hypercholesterolemia: A Case Report

Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by markedly elevated low-density lipoprotein cholesterol (LDL-C) levels and early cardiovascular disease. Despite intensive lipid-lowering therapy, achieving target LDL-C levels remains challenging, and many patients require lifelong LDL apheresis. We report a 33-year-old Mexican–Lebanese woman with confirmed HoFH and multiple comorbidities, including systemic lupus erythematosus. Severe hypercholesterolemia was evident from early childhood, with total cholesterol levels of approximately 800 mg/dL and development of xanthomas at age 3. The patient underwent long-term multimodal therapy, including statins, ezetimibe, PCSK9 inhibitors, and LDL apheresis initiated at age 9 and continued for approximately 20 years, achieving only partial lipid control. Evinacumab, an angiopoietin-like protein 3 (ANGPTL3) inhibitor, was initiated in adulthood as adjunctive therapy. Within two months, significant and sustained LDL-C reduction was achieved, allowing complete discontinuation of LDL apheresis. Follow-up demonstrated stable LDL-C levels between 180–225 mg/dL. This case highlights the clinical effectiveness of Evinacumab in patients with HoFH, demonstrating its potential to achieve sustained lipid reduction and eliminate the need for invasive apheresis. ANGPTL3 inhibition may represent a transformative strategy for improving long-term management and quality of life in this high-risk population, particularly in settings with limited access to apheresis.

Open article ↗



2026-09-15 | Evinacumab Across Different Lipid Phenotypes: A Systematic Review and Meta-Analysis.

Evinacumab, a monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3), has emerged as a promising therapeutic option for severe dyslipidemias. We have conducted a systematic review to evaluate its efficacy across different clinical settings. This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines and registered in PROSPERO (CRD42026142022). Eligible studies included randomized controlled trials, open-label extension studies, single-arm studies, and observational cohorts involving healthy individuals and patients with hypercholesterolemia or hypertriglyceridemia. Due to the small number of available studies and the absence of the data required for quantitative pooling in other clinical settings, a single-arm meta-analysis was performed exclusively in patients with hypercholesterolemia receiving evinacumab 15 mg/kg every 4 weeks. Overall, 17 studies were included in the systematic review. In hypercholesterolemia, evinacumab consistently reduced LDL-C levels by approximately 50%, with reductions ranging from 42% to 82% across studies. Long-term extension and real-world data confirmed sustained efficacy. Meta-analysis of seven studies including 357 patients receiving evinacumab 15 mg/kg intravenously every 4 weeks demonstrated significant reductions in LDL-C [mean difference (MD) - 48.56%], non-HDL-C (MD - 50.19%), apolipoprotein B (MD - 40.51%), and triglycerides (MD - 53.13%). In hypertriglyceridemia, qualitative evidence showed marked triglyceride lowering, particularly in multifactorial chylomicronemia syndrome, with reductions frequently exceeding 60-80%, whereas responses were limited in familial chylomicronemia syndrome. Evinacumab provides substantial and sustained lipid-lowering effects, particularly in homozygous familial hypercholesterolemia. Emerging evidence also supports a potential role in severe hypertriglyceridemia, although further studies are needed to define its clinical benefits in this setting.

Open article ↗



2026-08-11 | Clinical considerations on the use of evinacumab for the treatment of homozygous familial hypercholesterolemia

Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder that results in severely elevated low-density lipoprotein cholesterol (LDL-C) due to dysfunctional activity of the low-density lipoprotein receptor (LDLR) and impaired clearance of LDL-C. Individuals with HoFH require intensive lipid-lowering therapies (LLTs), ideally starting in early childhood, to aggressively lower LDL-C levels and mitigate risk of early-onset atherosclerotic cardiovascular disease caused by lifetime exposure to high LDL-C levels. However, most conventional LLTs lower LDL-C through an LDLR-dependent mechanism, limiting their effectiveness in individuals with HoFH, who have little to no LDLR activity. Evinacumab is a fully human monoclonal antibody against angiopoietin-like protein 3 (ANGPTL3), and has an LDLR-independent mechanism of action. By inhibiting ANGPTL3, evinacumab increases the activity of lipoprotein lipase and endothelial lipase, consequently increasing the clearance of LDL precursors and lowering LDL-C levels. Following its initial US Food and Drug Administration approval in 2021, evinacumab has been approved to treat individuals with HoFH from 1 year of age in the US and as young as 6 months of age in multiple other countries. Here, we describe the role of evinacumab in the HoFH treatment landscape, summarize the available clinical evidence for evinacumab, and provide practical guidance on its use from the clinician’s perspective.

Open article ↗



2026-07-12 | The Angiopoietin-like Protein (ANGPTL) Axis in Dyslipidemia: Mechanisms, Cardiovascular Risk, and Emerging Therapies.

The angiopoietin-like protein (ANGPTL) 3-4-8 axis has emerged as a central regulator of lipoprotein lipase and lipid metabolism. This review examines the mechanistic basis of ANGPTL pathway modulation and therapeutic implications for cardiovascular risk reduction across diverse phenotypes of dyslipidemia. Genetic studies demonstrate that loss-of-function variants in ANGPTL3 and ANGPTL4 are associated with lower triglycerides and decreased coronary artery disease risk. Pharmacologic inhibition of ANGPTL3 with monoclonal antibodies and RNA-based therapies reduces triglycerides, remnant cholesterol, low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (apoB) through mechanisms predominantly independent of the LDL receptor. Clinical trials with ANGPTL3 inhibitors have demonstrated marked LDL-C reductions in patients with homozygous familial hypercholesterolemia (HoFH), as well as broad lipid-lowering effects in patients with mixed dyslipidemia. Emerging strategies targeting the ANGPTL3/8 complex and ANGPTL4 further refine lipid-lowering effects, while early genome-editing data suggest the potential for durable ANGPTL3 suppression. Modulation of the ANGPTL-lipoprotein lipase axis is a novel strategy to address residual atherosclerotic risk beyond traditional LDL receptor-dependent therapies. ANGPTL3 inhibitors have been practice-changing in HoFH, and more broadly, ANGPTL-directed therapies hold promise for patients with mixed dyslipidemia to mitigate cardiovascular risk.

Open article ↗



2026-07-02 | Homozygous familial hypercholesterolemia, experience with Evinacumab treatment in two Mexican pediatric patients: case report

Homozygous familial hypercholesterolemia (HoFH) is a rare and life-threatening genetic disorder characterized by extremely elevated low-density lipoprotein cholesterol (LDL-C) levels from birth, leading to accelerated atherosclerotic cardiovascular disease and premature mortality. Conventional lipid-lowering therapies often provide insufficient LDL-C reduction, particularly in patients with minimal or absent LDL receptor (LDLR) function. Evinacumab, an angiopoietin-like protein 3 (ANGPTL3) inhibitor, lowers LDL-C independently of LDLR activity and represents a major therapeutic advance. Here we report two Mexican pediatric patients with HoFH who demonstrated profound LDL-C reductions following initiation of Evinacumab (59% and 68% within the first month of treatment), exceeding reductions observed in pivotal clinical trials. Both patients maintained sustained LDL-C reductions during long-term follow-up (up to 22 months). Importantly, temporary treatment interruption in both cases due to administrative and supply related difficulties limited access to Evinacumab was associated with marked rebound hypercholesterolemia. Reinitiation of therapy led to rapid and substantial lipid reduction, demonstrating a clear dechallenge–rechallenge effect and confirming the relevance of a continuous pharmacologic treatment with ANGPTL3 inhibition. Serial vascular imaging in one patient revealed partial regression of subclavian and carotid artery stenosis, as well as reduced aortic wall thickening following sustained LDL-C reduction; adding evidence to the recently described vascular improvement associated with Evinacumab therapy in pediatric HoFH. Both patients also experienced clinically meaningful improvements in quality of life, and treatment was well tolerated without serious adverse events.

Open article ↗



other
2026-07-18 | Precise hepatic base editing of ASGR1 enables robust and durable LDLR-independent lipid lowering in vivo.

Familial hypercholesterolemia (FH), most frequently caused by LDLR loss-of-function variants, is a common autosomal-dominant disorder that leads to early-onset, life-threatening cardiovascular disease. Therapeutic options for LDLR-deficient homozygous FH (HoFH) are very limited, motivating the development of durable, effective, and LDLR-independent gene therapies. Human genetic studies have linked ASGR1 loss-of-function variants with low serum cholesterol levels and significantly reduced cardiovascular risk, yet in vivo ASGR1 editing has not been explored as a therapeutic strategy for HoFH. Here, using an optimized hepatocyte-specific delivery platform, we achieved 57.6% liver-wide Asgr1 base editing in Ldlr-/- mice, yielding ∼95% reduction of hepatic ASGR1 expression and sustained 40%-50% reductions in serum LDL-cholesterol (LDL-C), total cholesterol (TC), and triglyceride levels, with a favorable safety profile. Importantly, moderate Asgr1 editing (32.0%) with partial protein suppression (58%) also conferred significant and durable lipid lowering, thereby defining a therapeutically relevant editing window aligned with ASGR1 suppression level in carriers of ASGR1 loss-of-function variants. Benchmarking against Angptl3 editing revealed comparable reductions in LDL-C and TC, while combined Asgr1/Angptl3 editing further enhanced serum cholesterol lowering, suggesting potential benefits of combined editing. Together, these findings establish hepatic ASGR1 base editing as a potent, durable, and LDLR-independent gene-therapy strategy for severe HoFH.

Open article ↗



2026-06-25 | A de novo LDLR mutation in severe familial hypercholesterolemia: case report, functional characterization, and a personalized gene correction strategy exploration.

Familial hypercholesterolemia (FH) is a genetic disorder of lipid metabolism characterized by elevated plasma low-density lipoprotein resulting in cardiovascular disease (CVD). The harmful mutations of LDLR are the main cause of FH. Especially, there is no effective treatment options for homozygous FH (HoFH) patients. Numerous FH cases have been reported, but most mutations remain unvalidated and lack gene correction studies. The study aims to assess the pathogenicity of a novel mutation, LDLR c.331C>T (p.Gln111Ter), and seek its gene correction strategy. The study systematically evaluated a female HoFH patient and her family. Using CRISPR/Cas9 technology, a Huh7 cell line carrying the point mutation was constructed. The impact of this mutation on LDLR protein expression was confirmed by qPCR, Western blot (WB), and immunofluorescence. A high-fidelity gene correction system targeting the LDLR c.331C>T point mutation was established based on the prime editing (PE) technology. The HoFH patient exhibited a biallelic LDLR mutation comprising an LDLR c.1693_1696 del GGCA inherited from her mather and a de novo LDLR c.331C>T (p.Gln111Ter) mutation. In vitro validation indicated that the mutation impaired normal LDLR protein expression, and the candidate gene editing system achieved approximately 98% correction efficiency. LDLR c.331C>T is a likely pathogenic mutation, which canbe precisely corrected by PE technology. The study expands the spectrum of likely pathogenic mutations in FH and holds promise for personalized, precise gene therapy through customized therapeutic systems, potentially alleviating or curing HoFH-a current challenge in conventional clinical management.

Open article ↗



2026-06-09 | Table 1_A de novo LDLR mutation in severe familial hypercholesterolemia: case report, functional characterization, and a personalized gene correction strategy exploration.docx

Background Familial hypercholesterolemia (FH) is a genetic disorder of lipid metabolism characterized by elevated plasma low-density lipoprotein resulting in cardiovascular disease (CVD). The harmful mutations of LDLR are the main cause of FH. Especially, there is no effective treatment options for homozygous FH (HoFH) patients. Numerous FH cases have been reported, but most mutations remain unvalidated and lack gene correction studies. The study aims to assess the pathogenicity of a novel mutation, LDLR c.331C>T (p.Gln111Ter), and seek its gene correction strategy. Methods The study systematically evaluated a female HoFH patient and her family. Using CRISPR/Cas9 technology, a Huh7 cell line carrying the point mutation was constructed. The impact of this mutation on LDLR protein expression was confirmed by qPCR, Western blot (WB), and immunofluorescence. A high-fidelity gene correction system targeting the LDLR c.331C>T point mutation was established based on the prime editing (PE) technology. Results The HoFH patient exhibited a biallelic LDLR mutation comprising an LDLR c.1693_1696 del GGCA inherited from her mather and a de novo LDLR c.331C>T (p.Gln111Ter) mutation. In vitro validation indicated that the mutation impaired normal LDLR protein expression, and the candidate gene editing system achieved approximately 98% correction efficiency. Conclusion LDLR c.331C>T is a likely pathogenic mutation, which canbe precisely corrected by PE technology. The study expands the spectrum of likely pathogenic mutations in FH and holds promise for personalized, precise gene therapy through customized therapeutic systems, potentially alleviating or curing HoFH—a current challenge in conventional clinical management.

Open article ↗



2026-04-17 | Severe polyarterial involvement in a 16-year-old with homozygous familial hypercholesterolaemia: a case report.

Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disorder characterized by an elevated plasma concentration of low-density lipoprotein cholesterol (LDL-C) starting at birth and a significantly increased risk of premature atherosclerotic cardiovascular disease. We report the case of a 16-year-old female patient, with no known consanguinity, presented to our cardiology department for anginal chest pain on exertion associated with headaches. She presented with characteristic morphological features of FH. Her lipid profile revealed extremely high LDL-C levels (706 mg/dL) and such extensive arterial and cutaneous involvement. This case underscores the importance of recognizing xanthomas and their association with an increased risk of coronary atherosclerosis.

Open article ↗



2026-02-26 | Hepatocyte-Specific Knockout of YAP Protects Against Atherosclerosis via Inhibition of ANGPTL3 in Mice.

Lipid-lowering therapy is a cornerstone in the treatment of atherosclerotic cardiovascular diseases. Although some lipid-lowering drugs have demonstrated positive effects in patients with atherosclerotic cardiovascular diseases, their effects are limited in those with homozygous familial hypercholesterolemia. It is essential to seek new lipid-lowering targets. YAP (Yes-associated protein) may be involved in lipid metabolism in the liver; therefore, we investigated the function of hepatocyte YAP in hyperlipidemia and atherosclerosis. Hyperlipidemia models were generated in apoE knockout (apoE-/-) mice or mice injected with adeno-associated virus 8-D377Y-mPCSK9, which degrades and deletes LDLR (low-density lipoprotein receptor), by being fed a high-cholesterol diet for 12 weeks. We measured the expression level of hepatic YAP in these apoE-/- mice. Next, we created YAPΔHep (hepatocyte-specific deletion of Yes-associated protein) apoE-/- mice to further determine the role of YAP in hyperlipidemia and atherosclerosis. AML12 (alpha mouse liver 12) cells and mice injected with AAV8-D377-mPCSK9 (adeno-associated virus 8 carrying the D377Y mutant of mouse proprotein convertase subtilisin/kexin type 9) or YAPΔHepapoE-/- mice were used to elucidate its mechanism. Finally, apoE-/- or LDLR knockout (LDLR-/-) mice were used to observe the therapeutic efficacy of adeno-associated virus 8-Alb (albumin)-shYAP (short hairpin RNA targeting for YAP) for hyperlipidemia and atherosclerosis. High-cholesterol diet-fed apoE-/- mice showed increased levels of YAP in the liver. Further investigation indicated that YAPΔHepapoE-/- mice exhibited lighter hyperlipidemia and atherosclerosis than YAPflox/floxapoE-/- mice fed with a high-cholesterol diet. Conversely, hepatocyte-specific overexpression of YAP (5S) deteriorated hyperlipidemia and atherosclerosis in high-cholesterol diet-fed apoE-/- mice. Furthermore, the lipid-lowering effect of YAP deficiency in hepatocytes was independent of LDLR. Hepatocyte-specific overexpression of ANGPTL3 (angiopoietin-like 3) aggravated hyperlipidemia and atherosclerosis in YAPΔHepapoE-/- mice, indicating that ANGPTL3 is responsible for the function of YAP in hyperlipidemia. Mechanistically, YAP upregulated ANGPTL3 via TEAD (TEA domain family member) 4 in hepatocytes independent of LDLR. Notably, adeno-associated virus 8-Alb-shYAP lowered lipid levels in apoE-/- or LDLR-/- mice. Taken together, our findings revealed a novel role for the YAP-TEAD4-ANGPTL3 axis in lipid metabolism independent of LDLR. Inhibition of hepatocyte YAP may be an effective lipid-lowering strategy for homozygous familial hypercholesterolemia.

Open article ↗



cell therapies
2026-09-26 | Real-World Outcomes of Lipoprotein Apheresis in Homozygous Familial Hypercholesterolemia: A Single-Center Longitudinal Experience.

Background: Lipoprotein apheresis (LA) remains an important treatment option for patients with homozygous familial hypercholesterolemia (HoFH) who have persistently severe low- density lipoprotein cholesterol (LDL-C) elevation despite intensive lipid-lowering therapy. Therapeutic plasma exchange (TPE) may serve as a temporary alternative when selective LA is unavailable. Methods: This retrospective, single-center longitudinal observational study evaluated six patients with HoFH treated with double-filtration plasmapheresis (DFPP) between 2010 and 2023. During a temporary interruption in DFPP availability, two patients underwent TPE. Pre- and post-procedure lipid levels were evaluated using paired measurements. Results: A total of 476 DFPP and 20 TPE procedures were performed. During DFPP, the median reductions in total cholesterol and LDL-C were 64.44% [57.14-70.21] and 67.53% [59.53-73.86], respectively, while the median reductions in high-density lipoprotein cholesterol (HDL-C) and triglycerides were 40.00% [30.63-48.00] and 48.63% [35.38-57.66]. Among TPE procedures with paired measurements, the corresponding median reductions were 71.11% [65.52-72.69] for total cholesterol, 70.97% [67.14-73.72] for LDL-C, 67.08% [62.92-70.83] for HDL-C, and 55.73% [38.68-63.33] for triglycerides. No serious adverse events were observed during DFPP. TPE was discontinued in one patient after chills and subfebrile fever. Conclusions: Long-term DFPP was associated with substantial acute lipid reductions in patients with HoFH. TPE also produced marked acute lipid reductions in two patients when DFPP was unavailable. However, the limited number of TPE-treated patients, repeated procedures within the same individuals, and overlapping evolocumab exposure preclude conclusions regarding comparative efficacy or safety. TPE may be considered as an individualized interim option when selective lipoprotein apheresis is temporarily unavailable.

Open article ↗



2026-06-26 | Women with Homozygous Familial Hypercholesterolemia and Impact on Reproductive Life from Menarche to Menopause: Long-Term Case Series Observational Study

Homozygous familial hypercholesterolemia (HoFH) is a genetic disease in which LDL-C is high at birth, causing cardiovascular disease. Reproductive issues in women are also caused by lipid-lowering therapies (LLTs) that must be interrupted during pregnancy and breastfeeding. The only safe choice during pregnancy is lipoprotein apheresis (LA), although there are limited data regarding fertility, pregnancy, and menopause. This long-term case series observational study examined 23 genetically confirmed HoFH women in a tertiary health facility, obtaining clinical, cardiovascular, biochemical, and reproductive information through medical records and structured interviews. Cardiovascular disease and aortic valve disease were found in 48% and 52%, respectively; four women died prematurely. Menarche (12.1 years) and menopause (52.0 years) were in the normal range. The majority of these had regular menstrual cycles; there was one case of polycystic ovary syndrome. Twelve women became spontaneously pregnant. Obstetric complications included preterm delivery, gestational diabetes, hypertension, and fetal growth restriction. This study showed that continuous LA during pregnancy was associated with better lipid control and maternal-fetal outcomes, but cardiovascular impairment was observed in the case of interruption of LLT. LLT interruption affects the inherited lipid disorder, and a very short period of breastfeeding is recommended. HoFH in women under treatment has no impact on the menstrual cycle or on the timing of menopause. Pregnancy is a high-risk condition that needs the care of a multidisciplinary team. The need to ensure continuous LA, systematic reproductive counseling, early cardiovascular examination, and aligned lifelong care is critical in maximizing the outcome of HoFH women.

Open article ↗



2026-06-24 | Synergistic "targeting and blockade" strategy via engineered exosomes and clinical ultrasound contrast agent for hepatocyte-targeted mRNA delivery.

Homozygous familial hypercholesterolemia (HoFH) presents a persistent and difficult-to-treat condition. This recalcitrance stems largely from loss-of-function mutations within the low-density lipoprotein receptor (LDLR) gene, which severely undermine the efficacy of standard therapeutic regimens. Here, we report a bioinspired "targeting and blockade" strategy for the efficient delivery of functional Ldlr mRNA to hepatocytes. This approach is realized through a rationally designed platform, Szd + AP@ExoE-Ldlr, which integrates APOA1-functionalized exosomes for hepatocyte-targeted delivery with a preemptive macrophage blockade using the clinical ultrasound contrast agent Sonazoid (Szd). The APOA1 modification confers specific recognition by the scavenger receptor class B type 1 on hepatocytes, while the pre-saturation of Kupffer cells with Szd significantly mitigates nonspecific clearance by the mononuclear phagocyte system (MPS). In a HoFH murine model, this synergistic strategy markedly enhanced the accumulation of exosomes in hepatocytes and achieved robust restoration of hepatic LDLR expression. Consequently, it elicited a profound correction of the atherogenic lipid profile and substantially attenuated the progression of atherosclerosis. A comprehensive biosafety evaluation confirmed the excellent biocompatibility of this platform. Our work provides a promising and broadly applicable solution for the treatment of liver-related genetic disorders by simultaneously overcoming the critical barriers of targeted delivery and MPS evasion.

Open article ↗



2026-04-17 | Liver transplantation in severe homozygous familial hypercholesterolaemia: a scoping review.

Liver transplantation is the only known potentially curative treatment for homozygous familial hypercholesterolaemia (HoFH). While this procedure often normalises low-density lipoprotein cholesterol (LDL-C) levels and can reverse coronary atherosclerosis and regress xanthomata, its long-term risks and benefits remain elusive. The purpose of this review was to examine the extant literature on the safety and efficacy of liver transplantation in patients with HoFH. A scoping review was conducted for relevant literature primarily focused on safety (e.g. surgical complications, rejection, immunosuppressive therapy, mortality) and effectiveness outcomes (e.g. serum LDL-C levels, xanthoma changes, atherosclerotic cardiovascular disease or events) of liver transplantation in severe HoFH. The PRISMA-ScR guideline was followed. We searched five databases (Medline, Embase, Global Health, Web of Science and CINAHL) from inception to September 2025. A total of 76 studies and 212 cases were included. The majority (53%) of studies were case reports. Liver transplantation was done mostly in children, genetically or phenotypically diagnosed with HoFH. The median follow-up time for individuals was 3.5 years. While the effectiveness of liver transplantation with reference to LDL-C reduction and xanthomata regression were well documented, long-term outcomes such as cardiovascular events and mortality were not consistently reported. While liver transplantation holds great potential for normalising circulatory LDL-C levels in patients with HoFH, due to the rare nature of HoFH, the current literature remains incomplete concerning its safety and efficacy. To fill this gap, future efforts should utilise liver transplantation registries, to increase sample size and standardise longer-term follow-up.

Open article ↗



2026-01-21 | Clinical and Subclinical Atherosclerotic Disease in Adolescents With Familial Hypercholesterolemia.

Familial hypercholesterolemia is primarily a disorder of reduced low-density lipoprotein (LDL) clearance, which can be inherited in either homozygous or heterozygous form. Despite the availability of various modalities to achieve target LDL cholesterol levels, inadequate control remains a significant risk factor for accelerated atherosclerosis in the pediatric population. Moreover, the occurrence of coronary artery disease in adolescents poses unique management challenges given the limited representation of this age group in clinical trials. We report 2 cases of coronary artery disease and 1 case of subclinical atherosclerosis in adolescent patients with genetically confirmed familial hypercholesterolemia, outlining the diagnostic work-up, challenges in achieving LDL cholesterol control, measures undertaken, including plasma exchange, and revascularization strategies using drug-eluting stents or drug-coated balloons, in accordance with current guidelines.

Open article ↗



small molecules
2026-09-18 | Current, novel and emerging lipid-lowering therapies in pediatric familial hypercholesterolemia.

Over the past decade, pharmacological treatment options for children with familial hypercholesterolemia (FH) have expanded considerably. The recent European Atherosclerosis Society consensus recommends more stringent LDL cholesterol (LDL-C) targets than previously advocated. Consequently, more children with FH are expected to become eligible for novel therapeutic options. This review summarizes established and emerging lipid-lowering therapies (LLT) evaluated in children, focusing on recent and ongoing clinical trials. Conventional LLT remains the cornerstone of FH treatment, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are approved for pediatric use and achieve significant LDL-C reductions; however, injectable administration and high costs limit their widespread use. Novel oral PCSK9 inhibitors are currently under investigation in clinical trials, and fixed-dose combinations may offer a more practical and cost-effective approach. Additionally, angiopoietin-like protein 3 inhibitors and microsomal triglyceride transfer protein inhibitors lower LDL-C in dependently of LDL receptor activity, making them particularly suitable for homozygous FH patients. The management of FH is entering a new therapeutic era. As therapeutic options expand and agents with greater LDL-C reductions become available, personalized treatment strategies will become increasingly important to achieve LDL-C targets and may ultimately shift from stepwise intensification approaches toward early intensive treatment.

Open article ↗



2026-08-01 | Lipoprotein apheresis: still needed in many patients, or soon a historical practice?

Abstract Lipoprotein apheresis (LA) has long been used as an ultima ratio therapy for patients with extreme lipid-driven cardiovascular risk. One perspective maintains that, despite major advances in lipid-lowering pharmacology and the emergence of gene-silencing therapies, LA remains indispensable for selected patients with homozygous familial hypercholesterolemia (HoFH), severe hypercholesterolemia refractory to maximal therapy, and isolated lipoprotein(a) [Lp(a)]–mediated progressive cardiovascular disease. An opposing view argues that modern and emerging pharmacological agents—PCSK9 inhibitors, inclisiran, bempedoic acid, evinacumab, and targeted Lp(a)-lowering antisense and small interfering RNA (siRNA) agents—have already rendered LA obsolete in almost all patients, with its remaining niche closing rapidly as outcome data accumulate. This combined manuscript juxtaposes the two positions in a streamlined form and concludes with a balanced conclusion of the future role of LA.

Open article ↗



2026-05-01 | Triazine Thiols Decrease Apolipoprotein B Secretion From Hepatocytes Through Inhibition of Human Carboxylesterase 1.

Homozygous familial hypercholesterolemia is an autosomal genetic disorder that generates increased levels of low-density lipoproteins in the serum. Elevated low-density lipoprotein results in hypercholesterolemia leading to potentially fatal cardiovascular disease. Patients with homozygous familial hypercholesterolemia are often refractory to standard cholesterol-lowering treatments. Some available pharmaceuticals developed specifically for homozygous familial hypercholesterolemia can elevate hepatic lipid levels and in other cases have limited accessibility. Previously, we identified a family of triazine thiol compounds that effectively reduce apolipoprotein B-100 secretion by hepatocytes. In mice with humanized livers, triazine thiols effectively lowered serum cholesterol, triglycerides, low-density lipoproteins and lipoprotein(a). Despite their effectiveness, the mode of action of triazine thiols was unknown. Affinity-based mass spectrometry, biochemical assays, molecular modeling, and gene-edited induced pluripotent stem cell-derived hepatocyte-like cells were used to identify and characterize the molecular target and mechanism of action of triazine thiols. Using affinity-based mass spectrometry, we identified Carboxylesterase 1 (CES1) as a triazine thiol binding protein. Biochemical assays demonstrated that triazine thiols are slow-binding, allosteric, covalent CES1-specific inhibitors. Molecular modeling identified a predicted binding site within CES1 near cysteine 390, and loss of this cysteine conferred resistance to triazine thiol-mediated inhibition. Moreover, hepatocyte-like cells derived from CES1-/- induced human pluripotent stem cells exhibited a significant reduction in APOB secretion, mimicking the effect of triazine thiol treatment. This study establishes triazine thiols as novel, highly specific carboxylesterase 1 inhibitors, providing insight into their mechanism and highlighting carboxylesterase 1 inhibition as an approach for treating hypercholesterolemia.

Open article ↗



2026-02-14 | The evolving therapeutic landscape of PCSK9 inhibition.

Cardiovascular disease remains the leading cause of death worldwide with low density lipoprotein being a major, yet modifiable, risk factor. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a central role in regulating low density lipoprotein (LDL) receptor expression. Naturally occurring loss-of-function variants in the PCSK9 gene result in lifelong lower LDL cholesterol (LDL-C) levels and significantly lower risk of atherosclerotic cardiovascular disease (ASCVD), providing strong genetic validation of PCSK9 as a therapeutic target. This insight has driven the development of therapies directed at PCSK9 for the management of hypercholesterolaemia, particularly in patients who fail to meet LDL-C targets despite maximally tolerated statin and ezetimibe. This is especially the case for patients who are statin intolerant or who have homozygous or heterozygous familial hypercholesterolaemia. The field has progressed rapidly from monoclonal antibodies to small interfering RNA and oral therapies, with gene editing strategies offering a potentially permanent inhibition of PCSK9. This review summarizes the evidence supporting the currently approved PCSK9 inhibitors. We discuss some novel therapies that are currently in development and consider some expanding indications for PCSK9 inhibition.

Open article ↗



2026-02-02 | Where lipoproteins meet T cells: LDL receptor in the growing landscape of immune modulation

T cells are highly adaptable immune cells that play a central role in host defense against infections, malignancies, and other threats. For effective immune responses, T cells must rapidly switch from a resting state to an active, energy-demanding state after recognizing antigen, and subsequently return to a quiescent state once the threat has been cleared. Tight regulation of this dynamic process is essential for immune homeostasis, as uncontrolled or prolonged T cell activation can result in chronic inflammation, tissue damage, or the development of autoimmune disease. T cell function is closely linked to intracellular metabolism. Nutrient uptake and energy metabolism are now recognized as key determinants of T cell activation, differentiation, and function. Within this context, the role of lipid metabolism, and specifically the use of lipoproteins by T cells, remains incompletely understood. Lipoproteins are the primary transporters for lipids such as cholesterol and triglycerides in the circulation. Low-density lipoprotein (LDL) delivers cholesterol to peripheral tissues, where it is essential for membrane synthesis, hormone production, and cellular growth. Cellular LDL uptake is largely mediated by the LDL receptor (LDLR), which is expressed by many cell types, including immune cells. Despite the fundamental importance of this pathway, its role in T cell biology has remained poorly characterized. This thesis investigates whether T cell responses can be modulated through manipulation of lipoprotein uptake and metabolism. Chapter 2 establishes a conceptual framework by introducing the field of immunometabolism, outlining how metabolic pathways and nutrient availability shape immune cell behavior, and highlighting their relevance in chronic inflammatory diseases such as atherosclerosis and cancer. Chapter 3 uncovers an immunological role for lipoproteins as carriers of lipid antigens, showing that circulating lipoproteins can transport lipid antigens to invariant natural killer T (iNKT) cells and induce their activation. Chapters 4 and 5 further delineate the role of LDLR-dependent lipoprotein uptake in CD4+ and CD8+ T cell subsets. Using cells derived from patients with homozygous familial hypercholesterolemia (hoFH), with mutations in the LDLR, this work demonstrates the importance of LDLR-mediated lipoprotein uptake in T cell function. LDLR-mediated uptake shaped CD4+ T cell activation, proliferation, and differentiation, particularly promoting the development of IL-10-producing immunoregulatory CD4+ T cells. In CD8+ T cells, PCSK9-mediated downregulation of LDLR impaired activation and effector function, whereas pharmacological inhibition of PCSK9 restored cytotoxic capacity, revealing opportunities to repurpose cholesterol-lowering therapies to enhance cancer immunotherapy. Chapter 6 explores strategies to improve tumor antigen presentation by increasing MHC class I expression, thereby enhancing CD8+ T cell-mediated tumor recognition. Finally, Chapter 7 emphasizes the metabolic flexibility of T cells, underscoring the therapeutic potential and complexity of targeting interconnected metabolic networks to modulate immune responses. Together, these findings establish lipoprotein metabolism as a key modulator of T cell immunity and underscore metabolic pathways as promising, though complex, targets for therapeutic intervention.

Open article ↗



oligonucleotides
2026-09-17 | Predictors of aortic stenosis in homozygous familial hypercholesterolemia: A study from the Canadian HoFH registry.

Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disease of low-density lipoprotein cholesterol (LDL-C) metabolism. This disease is associated with a major risk of both atherosclerotic cardiovascular disease and aortic stenosis (AS). The predictors of AS in this population are not well established. To investigate the univariable and multivariable predictors of AS in patients from the Canadian HoFH registry. Individuals from the Canadian HoFH registry were included in this retrospective longitudinal study. Clinical data were obtained from the treating physicians using a standardized questionnaire. Cox proportional hazards models were used to investigate the predictors of AS. The observed lifetime risk of AS was calculated using Kaplan-Meier estimates. Among the 67 patients with HoFH, 25 (37%) developed AS. The mean age at baseline was 22 ± 17 years and women represented 57% of the cohort. The independent predictors of AS were the baseline LDL-C (hazard ratio [HR] 1.22 [1.09-1.35], P = .0003) as well as the presence of at least 1 null genetic variant (HR 3.73 [1.41-9.86], P = .008). Having a baseline LDL-C value above 13 mmol/L was associated with an observed lifelong risk of developing AS approaching 100% within this cohort, whereas having a value below this threshold was associated with a risk of 27% (P = .0002). This is the first systematic evaluation within a national HoFH registry to report the univariable and multivariable predictors of AS in patients with HoFH. An external validation of our results in an international cohort of HoFH is warranted.

Open article ↗



2026-09-15 | Emerging Nucleic Acid-Based Therapies for Hypercholesterolemia with Focus on a New Modality, Liver-Directed miR-30c Analog C2.

Despite major advances in lipid-lowering therapies, a significant unmet need remains, particularly for patients with homozygous familial hypercholesterolemia (HoFH), severe heterozygous familial hypercholesterolemia (HeFH), and those who fail to achieve guideline-recommended LDL-C targets. Nucleic acid-based therapeutics have emerged as a transformative approach for treating hypercholesterolemia. Antisense oligonucleotides and small interfering RNAs (siRNAs) have demonstrated durable hepatic gene silencing and have led to approved therapies, while gene replacement and in vivo genome-editing strategies offer the potential for long-lasting, and possibly one-time, interventions. In parallel, microRNAs (miRNAs) have attracted increasing interest because of their ability to coordinately regulate multiple genes involved in lipoprotein metabolism, cholesterol transport, and lipid homeostasis. Human genetic studies further support the importance of miRNA-mediated regulation, exemplified by a rare ~2.5 kb deletion in the distal LDLR 3'UTR ("del2.5") that disrupts miRNA-binding sites and is associated with lifelong low LDL-C levels. This review summarizes recent advances, mechanisms of action, clinical progress, and remaining challenges across antisense oligonucleotides, siRNAs, gene therapy, genome editing, and emerging miRNA-based therapeutics for hypercholesterolemia. As an example of the latter approach, the liver-directed miR-30c analog C2 has demonstrated preclinical activity by coordinately reducing hepatic lipoprotein secretion and lipogenesis while enhancing cholesterol elimination, resulting in reduced LDL-C and atherosclerosis. However, it must be noted that these findings remain preclinical, and further optimization of delivery, pharmacokinetics, safety, and long-term efficacy will be required before clinical evaluation. Continued advances in RNA chemistry, targeted delivery, and genome engineering are expected to further expand the therapeutic landscape for dyslipidemia and cardiovascular disease.

Open article ↗



2026-06-04 | New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering.

ApoB is the structural protein of all atherogenic lipoproteins, including VLDLs (very-low-density lipoproteins), IDLs (intermediate-density lipoproteins), LDLs (low-density lipoproteins), chylomicron remnants, as well as Lp(a) (lipoprotein[a]). Because each lipoprotein particle contains a single apoB molecule, plasma apoB concentration reflects the number of circulating atherogenic particles. Genetic, epidemiological, and randomized clinical trial evidence consistently demonstrate that, on a per-particle basis, apoB is a more accurate causal determinant of atherosclerotic cardiovascular disease risk than LDL cholesterol alone. Beyond atherosclerosis, apo B48-containing chylomicrons play a central role in severe hypertriglyceridemia and, importantly, contribute to the risk of triglyceride-mediated acute pancreatitis. Most established therapies that reduce major cardiovascular events, including statins, ezetimibe, PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, and bempedoic acid, act primarily by enhancing LDL receptor-mediated clearance of apoB-containing particles. Other currently available therapies reduce LDL cholesterol as well as apoB through LDL receptor-independent mechanisms. Lomitapide, an inhibitor of MTP (microsomal triglyceride transfer protein), and evinacumab, a monoclonal antibody targeting ANGPTL3 (angiopoietin-like protein 3), reduce LDL cholesterol in homozygous familial hypercholesterolemia by decreasing triglyceride-rich apoB-containing lipoproteins upstream of LDL particle formation. Emerging therapeutic strategies targeting the angiopoietin-like protein axis, apo CIII, Lp(a), CETP (cholesteryl ester transfer protein), hepatic lipid flux, and incretin signaling expand the therapeutic landscape for modulating apoB-containing lipoproteins. Gene-targeted approaches, including gene editing, epigenome editing, small interfering RNA, and antisense oligonucleotides, as well as novel oral or injectable agents and combination therapies, further broaden opportunities for durable apoB modulation. Transitioning from an LDL cholesterol-centric to an apoB-centric framework may represent a biologically integrated strategy to reduce both atherosclerotic cardiovascular disease and triglyceride-mediated pancreatitis risk.

Open article ↗



2026-02-28 | Variable phenotype associated with compound LDLR gene mutations in familial hypercholesterolemia patients: Case series and clinical implications.

Homozygous familial hypercholesterolemia (HoFH) is a rare inherited disorder with an extremely elevated level of low-density lipoprotein (LDL) cholesterol (LDL-C) and accelerated premature coronary artery disease (PCAD). It is primarily caused by a single pathogenic variant of the LDL receptor (LDLR) gene. This report presents 2 rare and unrelated cases of HoFH with compound LDLR mutations. These 2 individuals presented with atypical clinical features and demonstrated variable degrees of hypercholesterolemia. Case 1 is a 36-year-old Malay woman identified during family cascade screening with a pretreated LDL-C of 8.5 mmol/L and a strong family history of PCAD. Case 2 is a 58-year-old Indian woman discovered to have a pretreated LDL-C of 5.2 mmol/L during routine health screening, without a significant family history of hypercholesterolemia or PCAD. Neither patient demonstrated tendon xanthomas or other lipid stigmata. Both patients underwent lipid profiling and targeted next-generation sequencing of FH-related genes (LDLR, APOB, PCSK9, ABCG5, and ABCG8). Two novel LDLR variants were identified in exon 18: c.2548-1_2548delGAinsTC (pathogenic) and c.2556_2557insTCAGTCTGG (p.Leu853Serfs*12; likely pathogenic) and classified according to American College of Medical Genetics and Genomics guidelines. Case 1 was homozygous for both variants, while Case 2 was homozygous for the splice-site variant and heterozygous for the frameshift variant. Both patients received guideline-directed lipid-lowering therapy and ongoing cardiovascular risk management. Despite biallelic LDLR variants, both patients demonstrated relatively milder hypercholesterolemia and absence of classical HoFH stigmata. The LDLR variants located in exon 18 affecting the cytoplasmic tail domain may be associated with attenuated clinical expression. Recognition of genotype-phenotype variability is crucial for accurate diagnosis, risk stratification, and individualized management of HoFH.

Open article ↗



2026-02-14 | A nationwide genetic and phenotypic spectrum of 63 probands of homozygous familial hypercholesterolemia in Taiwan.

The genetic and phenotypic spectrum of homozygous familial hypercholesterolemia (HoFH) in Han Chinese populations remains insufficiently defined. To delineate the nationwide genetic and clinical features of HoFH in Taiwan, including true HoFH, double heterozygous FH (HeFH), and compound HeFH. Patients with clinically diagnosed probable or definite FH enrolled in the Taiwan FH Registry who underwent genetic testing between 2006 and 2025 were analyzed. A comprehensive workflow integrating microarray assay, mass spectrometry, targeted next-generation sequencing, and multiplex ligation-dependent probe amplification was implemented. Variants were classified using American College of Medical Genetics and Genomics guidelines. Of 1479 screened individuals, 63 were genetically confirmed to have HoFH (mean age, 32.8 ± 22.7 years), including 28.6% with atherosclerotic vascular disease. The cohort comprised 14 true HoFH (including homozygous APOB variants), 6 double HeFH, and 43 compound HeFH. The highest documented low-density lipoprotein cholesterol (LDL-C) levels were 357.3 ± 123.5 mg/dL in true HoFH, 347.3 ± 39.2 mg/dL in double HeFH, and 443.5 ± 170.9 mg/dL in compound HeFH. The most frequent genotypes were LDLR [IVS2+4A>T];[IVS2+4A>T] in true HoFH, [APOB p.R3527W];[LDLR IVS2+4A>T] and [APOB p.R3527W];[LDLR p.D90N] in double HeFH, and LDLR [p.D90N];[p.C329Y] in compound HeFH. Patients with double HeFH had lower LDL-C levels and fewer xanthomas than those with LDLR homozygosity or compound mutations, while individuals with homozygous LDLR exon deletions/duplications had the highest LDL-C levels. This nationwide study provides the first comprehensive genetic and clinical characterization of HoFH in Taiwan. Our findings highlight the importance of precise genetic diagnosis and early detection strategies in improving outcomes for this high-risk population.

Open article ↗



antibodies
2026-09-23 | Evinacumab Enables Discontinuation of LDL Apheresis in Homozygous Familial Hypercholesterolemia: A Case Report

Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by markedly elevated low-density lipoprotein cholesterol (LDL-C) levels and early cardiovascular disease. Despite intensive lipid-lowering therapy, achieving target LDL-C levels remains challenging, and many patients require lifelong LDL apheresis. We report a 33-year-old Mexican–Lebanese woman with confirmed HoFH and multiple comorbidities, including systemic lupus erythematosus. Severe hypercholesterolemia was evident from early childhood, with total cholesterol levels of approximately 800 mg/dL and development of xanthomas at age 3. The patient underwent long-term multimodal therapy, including statins, ezetimibe, PCSK9 inhibitors, and LDL apheresis initiated at age 9 and continued for approximately 20 years, achieving only partial lipid control. Evinacumab, an angiopoietin-like protein 3 (ANGPTL3) inhibitor, was initiated in adulthood as adjunctive therapy. Within two months, significant and sustained LDL-C reduction was achieved, allowing complete discontinuation of LDL apheresis. Follow-up demonstrated stable LDL-C levels between 180–225 mg/dL. This case highlights the clinical effectiveness of Evinacumab in patients with HoFH, demonstrating its potential to achieve sustained lipid reduction and eliminate the need for invasive apheresis. ANGPTL3 inhibition may represent a transformative strategy for improving long-term management and quality of life in this high-risk population, particularly in settings with limited access to apheresis.

Open article ↗



2026-09-15 | Evinacumab Across Different Lipid Phenotypes: A Systematic Review and Meta-Analysis.

Evinacumab, a monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3), has emerged as a promising therapeutic option for severe dyslipidemias. We have conducted a systematic review to evaluate its efficacy across different clinical settings. This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines and registered in PROSPERO (CRD42026142022). Eligible studies included randomized controlled trials, open-label extension studies, single-arm studies, and observational cohorts involving healthy individuals and patients with hypercholesterolemia or hypertriglyceridemia. Due to the small number of available studies and the absence of the data required for quantitative pooling in other clinical settings, a single-arm meta-analysis was performed exclusively in patients with hypercholesterolemia receiving evinacumab 15 mg/kg every 4 weeks. Overall, 17 studies were included in the systematic review. In hypercholesterolemia, evinacumab consistently reduced LDL-C levels by approximately 50%, with reductions ranging from 42% to 82% across studies. Long-term extension and real-world data confirmed sustained efficacy. Meta-analysis of seven studies including 357 patients receiving evinacumab 15 mg/kg intravenously every 4 weeks demonstrated significant reductions in LDL-C [mean difference (MD) - 48.56%], non-HDL-C (MD - 50.19%), apolipoprotein B (MD - 40.51%), and triglycerides (MD - 53.13%). In hypertriglyceridemia, qualitative evidence showed marked triglyceride lowering, particularly in multifactorial chylomicronemia syndrome, with reductions frequently exceeding 60-80%, whereas responses were limited in familial chylomicronemia syndrome. Evinacumab provides substantial and sustained lipid-lowering effects, particularly in homozygous familial hypercholesterolemia. Emerging evidence also supports a potential role in severe hypertriglyceridemia, although further studies are needed to define its clinical benefits in this setting.

Open article ↗



2026-08-11 | Clinical considerations on the use of evinacumab for the treatment of homozygous familial hypercholesterolemia

Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder that results in severely elevated low-density lipoprotein cholesterol (LDL-C) due to dysfunctional activity of the low-density lipoprotein receptor (LDLR) and impaired clearance of LDL-C. Individuals with HoFH require intensive lipid-lowering therapies (LLTs), ideally starting in early childhood, to aggressively lower LDL-C levels and mitigate risk of early-onset atherosclerotic cardiovascular disease caused by lifetime exposure to high LDL-C levels. However, most conventional LLTs lower LDL-C through an LDLR-dependent mechanism, limiting their effectiveness in individuals with HoFH, who have little to no LDLR activity. Evinacumab is a fully human monoclonal antibody against angiopoietin-like protein 3 (ANGPTL3), and has an LDLR-independent mechanism of action. By inhibiting ANGPTL3, evinacumab increases the activity of lipoprotein lipase and endothelial lipase, consequently increasing the clearance of LDL precursors and lowering LDL-C levels. Following its initial US Food and Drug Administration approval in 2021, evinacumab has been approved to treat individuals with HoFH from 1 year of age in the US and as young as 6 months of age in multiple other countries. Here, we describe the role of evinacumab in the HoFH treatment landscape, summarize the available clinical evidence for evinacumab, and provide practical guidance on its use from the clinician’s perspective.

Open article ↗



2026-07-12 | The Angiopoietin-like Protein (ANGPTL) Axis in Dyslipidemia: Mechanisms, Cardiovascular Risk, and Emerging Therapies.

The angiopoietin-like protein (ANGPTL) 3-4-8 axis has emerged as a central regulator of lipoprotein lipase and lipid metabolism. This review examines the mechanistic basis of ANGPTL pathway modulation and therapeutic implications for cardiovascular risk reduction across diverse phenotypes of dyslipidemia. Genetic studies demonstrate that loss-of-function variants in ANGPTL3 and ANGPTL4 are associated with lower triglycerides and decreased coronary artery disease risk. Pharmacologic inhibition of ANGPTL3 with monoclonal antibodies and RNA-based therapies reduces triglycerides, remnant cholesterol, low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (apoB) through mechanisms predominantly independent of the LDL receptor. Clinical trials with ANGPTL3 inhibitors have demonstrated marked LDL-C reductions in patients with homozygous familial hypercholesterolemia (HoFH), as well as broad lipid-lowering effects in patients with mixed dyslipidemia. Emerging strategies targeting the ANGPTL3/8 complex and ANGPTL4 further refine lipid-lowering effects, while early genome-editing data suggest the potential for durable ANGPTL3 suppression. Modulation of the ANGPTL-lipoprotein lipase axis is a novel strategy to address residual atherosclerotic risk beyond traditional LDL receptor-dependent therapies. ANGPTL3 inhibitors have been practice-changing in HoFH, and more broadly, ANGPTL-directed therapies hold promise for patients with mixed dyslipidemia to mitigate cardiovascular risk.

Open article ↗



2026-07-02 | Homozygous familial hypercholesterolemia, experience with Evinacumab treatment in two Mexican pediatric patients: case report

Homozygous familial hypercholesterolemia (HoFH) is a rare and life-threatening genetic disorder characterized by extremely elevated low-density lipoprotein cholesterol (LDL-C) levels from birth, leading to accelerated atherosclerotic cardiovascular disease and premature mortality. Conventional lipid-lowering therapies often provide insufficient LDL-C reduction, particularly in patients with minimal or absent LDL receptor (LDLR) function. Evinacumab, an angiopoietin-like protein 3 (ANGPTL3) inhibitor, lowers LDL-C independently of LDLR activity and represents a major therapeutic advance. Here we report two Mexican pediatric patients with HoFH who demonstrated profound LDL-C reductions following initiation of Evinacumab (59% and 68% within the first month of treatment), exceeding reductions observed in pivotal clinical trials. Both patients maintained sustained LDL-C reductions during long-term follow-up (up to 22 months). Importantly, temporary treatment interruption in both cases due to administrative and supply related difficulties limited access to Evinacumab was associated with marked rebound hypercholesterolemia. Reinitiation of therapy led to rapid and substantial lipid reduction, demonstrating a clear dechallenge–rechallenge effect and confirming the relevance of a continuous pharmacologic treatment with ANGPTL3 inhibition. Serial vascular imaging in one patient revealed partial regression of subclavian and carotid artery stenosis, as well as reduced aortic wall thickening following sustained LDL-C reduction; adding evidence to the recently described vascular improvement associated with Evinacumab therapy in pediatric HoFH. Both patients also experienced clinically meaningful improvements in quality of life, and treatment was well tolerated without serious adverse events.

Open article ↗



other
2026-07-18 | Precise hepatic base editing of ASGR1 enables robust and durable LDLR-independent lipid lowering in vivo.

Familial hypercholesterolemia (FH), most frequently caused by LDLR loss-of-function variants, is a common autosomal-dominant disorder that leads to early-onset, life-threatening cardiovascular disease. Therapeutic options for LDLR-deficient homozygous FH (HoFH) are very limited, motivating the development of durable, effective, and LDLR-independent gene therapies. Human genetic studies have linked ASGR1 loss-of-function variants with low serum cholesterol levels and significantly reduced cardiovascular risk, yet in vivo ASGR1 editing has not been explored as a therapeutic strategy for HoFH. Here, using an optimized hepatocyte-specific delivery platform, we achieved 57.6% liver-wide Asgr1 base editing in Ldlr-/- mice, yielding ∼95% reduction of hepatic ASGR1 expression and sustained 40%-50% reductions in serum LDL-cholesterol (LDL-C), total cholesterol (TC), and triglyceride levels, with a favorable safety profile. Importantly, moderate Asgr1 editing (32.0%) with partial protein suppression (58%) also conferred significant and durable lipid lowering, thereby defining a therapeutically relevant editing window aligned with ASGR1 suppression level in carriers of ASGR1 loss-of-function variants. Benchmarking against Angptl3 editing revealed comparable reductions in LDL-C and TC, while combined Asgr1/Angptl3 editing further enhanced serum cholesterol lowering, suggesting potential benefits of combined editing. Together, these findings establish hepatic ASGR1 base editing as a potent, durable, and LDLR-independent gene-therapy strategy for severe HoFH.

Open article ↗



2026-06-25 | A de novo LDLR mutation in severe familial hypercholesterolemia: case report, functional characterization, and a personalized gene correction strategy exploration.

Familial hypercholesterolemia (FH) is a genetic disorder of lipid metabolism characterized by elevated plasma low-density lipoprotein resulting in cardiovascular disease (CVD). The harmful mutations of LDLR are the main cause of FH. Especially, there is no effective treatment options for homozygous FH (HoFH) patients. Numerous FH cases have been reported, but most mutations remain unvalidated and lack gene correction studies. The study aims to assess the pathogenicity of a novel mutation, LDLR c.331C>T (p.Gln111Ter), and seek its gene correction strategy. The study systematically evaluated a female HoFH patient and her family. Using CRISPR/Cas9 technology, a Huh7 cell line carrying the point mutation was constructed. The impact of this mutation on LDLR protein expression was confirmed by qPCR, Western blot (WB), and immunofluorescence. A high-fidelity gene correction system targeting the LDLR c.331C>T point mutation was established based on the prime editing (PE) technology. The HoFH patient exhibited a biallelic LDLR mutation comprising an LDLR c.1693_1696 del GGCA inherited from her mather and a de novo LDLR c.331C>T (p.Gln111Ter) mutation. In vitro validation indicated that the mutation impaired normal LDLR protein expression, and the candidate gene editing system achieved approximately 98% correction efficiency. LDLR c.331C>T is a likely pathogenic mutation, which canbe precisely corrected by PE technology. The study expands the spectrum of likely pathogenic mutations in FH and holds promise for personalized, precise gene therapy through customized therapeutic systems, potentially alleviating or curing HoFH-a current challenge in conventional clinical management.

Open article ↗



2026-06-09 | Table 1_A de novo LDLR mutation in severe familial hypercholesterolemia: case report, functional characterization, and a personalized gene correction strategy exploration.docx

Background Familial hypercholesterolemia (FH) is a genetic disorder of lipid metabolism characterized by elevated plasma low-density lipoprotein resulting in cardiovascular disease (CVD). The harmful mutations of LDLR are the main cause of FH. Especially, there is no effective treatment options for homozygous FH (HoFH) patients. Numerous FH cases have been reported, but most mutations remain unvalidated and lack gene correction studies. The study aims to assess the pathogenicity of a novel mutation, LDLR c.331C>T (p.Gln111Ter), and seek its gene correction strategy. Methods The study systematically evaluated a female HoFH patient and her family. Using CRISPR/Cas9 technology, a Huh7 cell line carrying the point mutation was constructed. The impact of this mutation on LDLR protein expression was confirmed by qPCR, Western blot (WB), and immunofluorescence. A high-fidelity gene correction system targeting the LDLR c.331C>T point mutation was established based on the prime editing (PE) technology. Results The HoFH patient exhibited a biallelic LDLR mutation comprising an LDLR c.1693_1696 del GGCA inherited from her mather and a de novo LDLR c.331C>T (p.Gln111Ter) mutation. In vitro validation indicated that the mutation impaired normal LDLR protein expression, and the candidate gene editing system achieved approximately 98% correction efficiency. Conclusion LDLR c.331C>T is a likely pathogenic mutation, which canbe precisely corrected by PE technology. The study expands the spectrum of likely pathogenic mutations in FH and holds promise for personalized, precise gene therapy through customized therapeutic systems, potentially alleviating or curing HoFH—a current challenge in conventional clinical management.

Open article ↗



2026-04-17 | Severe polyarterial involvement in a 16-year-old with homozygous familial hypercholesterolaemia: a case report.

Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disorder characterized by an elevated plasma concentration of low-density lipoprotein cholesterol (LDL-C) starting at birth and a significantly increased risk of premature atherosclerotic cardiovascular disease. We report the case of a 16-year-old female patient, with no known consanguinity, presented to our cardiology department for anginal chest pain on exertion associated with headaches. She presented with characteristic morphological features of FH. Her lipid profile revealed extremely high LDL-C levels (706 mg/dL) and such extensive arterial and cutaneous involvement. This case underscores the importance of recognizing xanthomas and their association with an increased risk of coronary atherosclerosis.

Open article ↗



2026-02-26 | Hepatocyte-Specific Knockout of YAP Protects Against Atherosclerosis via Inhibition of ANGPTL3 in Mice.

Lipid-lowering therapy is a cornerstone in the treatment of atherosclerotic cardiovascular diseases. Although some lipid-lowering drugs have demonstrated positive effects in patients with atherosclerotic cardiovascular diseases, their effects are limited in those with homozygous familial hypercholesterolemia. It is essential to seek new lipid-lowering targets. YAP (Yes-associated protein) may be involved in lipid metabolism in the liver; therefore, we investigated the function of hepatocyte YAP in hyperlipidemia and atherosclerosis. Hyperlipidemia models were generated in apoE knockout (apoE-/-) mice or mice injected with adeno-associated virus 8-D377Y-mPCSK9, which degrades and deletes LDLR (low-density lipoprotein receptor), by being fed a high-cholesterol diet for 12 weeks. We measured the expression level of hepatic YAP in these apoE-/- mice. Next, we created YAPΔHep (hepatocyte-specific deletion of Yes-associated protein) apoE-/- mice to further determine the role of YAP in hyperlipidemia and atherosclerosis. AML12 (alpha mouse liver 12) cells and mice injected with AAV8-D377-mPCSK9 (adeno-associated virus 8 carrying the D377Y mutant of mouse proprotein convertase subtilisin/kexin type 9) or YAPΔHepapoE-/- mice were used to elucidate its mechanism. Finally, apoE-/- or LDLR knockout (LDLR-/-) mice were used to observe the therapeutic efficacy of adeno-associated virus 8-Alb (albumin)-shYAP (short hairpin RNA targeting for YAP) for hyperlipidemia and atherosclerosis. High-cholesterol diet-fed apoE-/- mice showed increased levels of YAP in the liver. Further investigation indicated that YAPΔHepapoE-/- mice exhibited lighter hyperlipidemia and atherosclerosis than YAPflox/floxapoE-/- mice fed with a high-cholesterol diet. Conversely, hepatocyte-specific overexpression of YAP (5S) deteriorated hyperlipidemia and atherosclerosis in high-cholesterol diet-fed apoE-/- mice. Furthermore, the lipid-lowering effect of YAP deficiency in hepatocytes was independent of LDLR. Hepatocyte-specific overexpression of ANGPTL3 (angiopoietin-like 3) aggravated hyperlipidemia and atherosclerosis in YAPΔHepapoE-/- mice, indicating that ANGPTL3 is responsible for the function of YAP in hyperlipidemia. Mechanistically, YAP upregulated ANGPTL3 via TEAD (TEA domain family member) 4 in hepatocytes independent of LDLR. Notably, adeno-associated virus 8-Alb-shYAP lowered lipid levels in apoE-/- or LDLR-/- mice. Taken together, our findings revealed a novel role for the YAP-TEAD4-ANGPTL3 axis in lipid metabolism independent of LDLR. Inhibition of hepatocyte YAP may be an effective lipid-lowering strategy for homozygous familial hypercholesterolemia.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

19 orphan drug designations for Homozygous familial hypercholesterolemia, including 7 approved therapies.

19 orphan drug designations for Homozygous familial hypercholesterolemia, including 7 approved therapies.

Drug

Therapy type

Orphan designation

Clinical trial status

Sponsor

messenger RNA encoding for adenine base editor protein and guide RNA targeting the angiopoietin like 3 (ANGPTL3) gene

gene editing enzymes

FDA
2026-09-11

Phase I
Ongoing

Verve Therapeutics, a Wholly Owned Subs of Eli Lilly and Co

recombinant adeno-associated virus serotype 8 vector encoding human low-density lipoprotein receptor

gene therapies

FDA
2025-08-14

Phase I
Ongoing

NGGT INC.

mRNA encoding the cholesterol degrading platform (CDP) fusion protein

RNAs

FDA
2025-05-15

—

Repair Biotechnologies, Inc.

bempedoic acid

small molecules

FDA
2021-04-05

Phase III
Terminated

Esperion Therapeutics, Inc.

Double stranded oligomer RNA interference-based liver targeted therapeutic directed against the ANGPTL3 gene

oligonucleotides

FDA
2019-07-15

Phase III
Ongoing

Arrowhead Pharmaceuticals, Inc.

inclisiran [Leqvio]

RNAs

FDA
2018-01-22

Approved
2026-02-12

Novartis Pharmaceuticals Corporation

apolipoprotein E mimetic peptide (AEM-28(R)-14)

proteins

FDA
2017-08-07

Phase I/II
Terminated

LipimetiX Development, LLC

alirocumab [Praluent]

antibodies

FDA
2017-06-15

Approved
2021-04-01

Regeneron Pharmaceuticals, Inc.

evinacumab-dgnb [Evkeeza]

antibodies

FDA
2016-02-08

Approved
2021-02-11

Regeneron Pharmaceuticals, Inc.

2-[4-[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate

small molecules

FDA
2015-03-18

Phase II
Terminated

Gilead Sciences, Inc.

rosuvastatin [Crestor]

small molecules

FDA
2014-02-14

Approved
2016-05-27

iPR Pharmaceuticals, Inc.

gemcabene

small molecules

FDA
2014-02-06

Phase II
Terminated

MetaVia, Inc.

evolocumab [Repatha]

antibodies

FDA
2013-09-12

Approved
2015-08-27

Amgen Inc.

apolipoprotein E mimetic peptide

peptides

FDA
2012-12-03

Phase I/II
Terminated

LipimetiX Development, LLC

Adeno-Associated Viral Vector Expressing Low-Density Lipoprotein Receptor

gene therapies

FDA
2012-01-31

Phase I/II
Terminated

ReGenX Biosciences LLC

lomitapide [Juxtapid]

small molecules

FDA
2007-10-23

Approved
2012-12-21

Chiesi Farmaceutici S.p.A.

mipomersen [KYNAMRO]

oligonucleotides

FDA
2006-05-23

Approved
2013-01-29

Kastle Therapeutics, LLC

Implitapide

small molecules

FDA
2004-08-13

Phase II
Terminated

Medical Research Laboratories International

Sodium dichloroacetate

small molecules

FDA
1990-06-11

—

Stacpoole, Peter W. M.D., Ph.D.

“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.